J&J’s Forecast Misses Analyst Estimates, May Sell Unit

Johnson & Johnson, the world’s biggest maker of healthcare products, may sell its $2.2 billion diagnostics unit for blood and cholesterol tests as the company focuses on genetic screening to complement its drug pipeline.
Businessweek